Nueclear Web Banner
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression


 Department of Obstetrics and Gynecology, Binzhou Medical University Hospital, Binzhou, Shandong, P.R. China

Correspondence Address:
Li Li,
Department of Obstetrics and Gynecology, Binzhou Medical University Hospital, Binzhou, Shandong 256603
P.R. China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Aim of Study: Bevacizumab (BV) is broadly used to treat a number of cancers; however, BV resistance mechanisms and strategies to overcome this resistance are yet to be determined. Materials and Methods: In this study, we used ovarian xenograft model to evaluate the underlying resistance mechanisms of BV in ovarian cancer treatment. Results: Our results showed that EphB4 was overexpressed in BV-resistant xenograft models instead of other common receptor tyrosine kinases. In addition, when coadministrated with EphB4 blocker NVP-BHG712, the antitumor effect of BV was significantly enhanced in the resistant model, further confirmed the role of EphB4 in BV-resistant ovarian cancer. These results indicate that NVP-BHG712 reverses EphB4 overexpression-mediated resistance to BV. Conclusion: These findings represent a guide for the design of future medication strategy and may be useful in guiding the use of BV in combination with NVP-BHG712 in patients with resistance or intolerance ovarian cancer.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Li L
    -  Nan F
    -  Guo Q
    -  Guan D
    -  Zhou C
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed265    
    PDF Downloaded10    

Recommend this journal